Pharma Mar | PHM - Cash And Equivalent


Pharma Mar reported EUR19.34M in Cash and Equivalent for its fiscal quarter ending in June of 2026.





Cash And Equivalent Change Date
Akebia Therapeutics USD 159.25M 3.71M Sep/2026
Alaunos Therapeutics USD 124K 230K Jun/2026
Almirall EUR 354.57M 16.8M Jun/2026
Avita Medical AUD 9.14M 1.1M Jun/2026
Dianthus Therapeutics USD 55.69M 54.86M Sep/2026
Ionis Pharmaceuticals USD 296.3M 53.76M Sep/2026
IQVIA Holdings USD 2.25B 340M Sep/2026
Laboratorios Farma EUR 46.11M 18.92M Jun/2025
Moderna USD 1.2B 528M Sep/2026
Organon & Co USD 1.46B 323M Sep/2026
Pharma Mar EUR 19.34M 29.53M Jun/2026
Revvity USD 592.8M 430.14M Sep/2026
Tectonic Therapeutic USD 227.07M 9.83M Jun/2026
Viatris USD 1.79B 902.7M Sep/2026
Xeris Pharmaceuticals USD 131.08M 9.33M Sep/2026